All Stories

  1. Urinary proteomic signature of exercise intolerance in patients at risk of heart failure: evidence from the HOMAGE trial
  2. Too Hot To Sleep? Circadian Temperature Control in Heart Failure
  3. Does the global prevalence of heart failure now exceed 600 million people? From guesswork to evidence
  4. Congestion and renal function in patients with chronic heart failure
  5. Congestion, obesity and survival in chronic heart failure
  6. Beyond Chronological Age: Why Frailty Matters in Heart Failure
  7. Do we need exercise echocardiography to diagnose HFpEF? Not at all
  8. Association between body mass index, plasma N-terminal pro-B-type natriuretic peptide, symptoms and outcome in patients referred for investigation of suspected heart failure
  9. Effect of correcting iron deficiency on the risk of serious infection in heart failure: Insights from the IRONMAN trial
  10. Managing congestive heart failure: It is mostly about water, not salt!
  11. Adjudication of Hospitalizations and Deaths in the IRONMAN Trial of Intravenous Iron for Heart Failure
  12. Association of non-cardiac comorbidities and sex with long-term Re-hospitalization for heart failure
  13. Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trial
  14. Integrative assessment of congestion in heart failure using ultrasound imaging
  15. REVOLUTION in Heart Failure Care and SELECT Highlights From the European Society of Cardiology-Heart Failure Association Heart Failure & World Congress on Acute Heart Failure 2024
  16. Heart rate reactivity, recovery, and endurance of the incremental shuttle walk test in patients prone to heart failure
  17. Disease progression in chronic heart failure is linear: Insights from multistate modelling
  18. Managing water and salt balance in heart failure: Is there anything else to consider other than diet and diuretics?
  19. Loop diuretic therapy with or without heart failure: impact on prognosis
  20. Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial
  21. The Impact of Ferric Derisomaltose on Cardiovascular and Noncardiovascular Events in Patients With Anemia, Iron Deficiency, and Heart Failure With Reduced Ejection Fraction
  22. Prognostic implication of lung ultrasound in heart failure: a pooled analysis of international cohorts
  23. Proteomic profiles of left atrial volume and its influence on response to spironolactone: Findings from the HOMAGE trial and STANISLAS cohort
  24. Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial
  25. Low Serum Ferritin Might Predict Incident Heart Failure
  26. Multi-modality assessment of congestion in acute heart failure: Associations with left ventricular ejection fraction and prognosis
  27. ACHIEVE conference proceedings: implementing action plans to reduce and control hypertension burden in Africa
  28. Priorities to reduce the burden of hypertension in Africa through ACHIEVE
  29. Estimation of Right Atrial Pressure by Ultrasound-Assessed Jugular Vein Distensibility in Patients With Heart Failure
  30. Reply to ‘Vasodilators in congestive heart failure: The perfect weapon aiming just off the target?’
  31. Circulating cytokines and risk of developing hypertension: A systematic review and meta-analysis
  32. Atrial myopathy and heart failure with preserved ejection fraction: When a label does more harm than good?
  33. Medicines optimization prior to discharge in patients admitted to hospital with heart failure
  34. How to diagnose and treat venous congestion in heart failure
  35. Impact of vasodilators on diuretic response in patients with congestive heart failure: A mechanistic trial of cimlanod (BMS‐986231)
  36. Multiple Cardiac Biomarkers to Improve Prediction of Cardiovascular Events: Findings from the Generation Scotland Scottish Family Health Study
  37. Phenotyping patients with ischaemic heart disease at risk of developing heart failure: an analysis of the HOMAGE trial
  38. Hospital admissions in the last year of life of patients with heart failure
  39. Lung ultrasound in acute and chronic heart failure: a clinical consensus statement of the European Association of Cardiovascular Imaging (EACVI)
  40. Influence of serum transferrin concentration on diagnostic criteria for iron deficiency in chronic heart failure
  41. Coronary revascularization for heart failure with coronary artery disease: A systematic review and meta‐analysis of randomized trials
  42. Defining Heart Failure Based on Imaging the Heart and Beyond
  43. Assessment of haemoglobin and serum markers of iron deficiency in people with cardiovascular disease
  44. Correction to: Congestion and Use of Diuretics in Heart Failure and Cardiomyopathies: A Practical Guide
  45. Protein Biomarkers of New-Onset Heart Failure: Insights From the Heart Omics and Ageing Cohort, the Atherosclerosis Risk in Communities Study, and the Framingham Heart Study
  46. A machine learning‐derived echocardiographic algorithm identifies people at risk of heart failure with distinct cardiac structure, function, and response to spironolactone: findings from the HOMAGE trial
  47. Congestion and Use of Diuretics in Heart Failure and Cardiomyopathies: a Practical Guide
  48. Urinary Proteomic Signature of Mineralocorticoid Receptor Antagonism by Spironolactone: Evidence from the Randomized-Controlled HOMAGE and PRIORITY Trials
  49. Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide: Pooled analysis of three randomized trials
  50. Inferior vena cava diameter is associated with prognosis in patients with chronic heart failure independent of tricuspid regurgitation velocity
  51. Intravenous iron in patients with heart failure and iron deficiency: an updated meta‐analysis
  52. Redefining both iron deficiency and anaemia in cardiovascular disease
  53. Effect of Spironolactone on QRS Duration in Patients at Risk for Heart Failure (from the HOMAGE Trial)
  54. Estimating nuclear scanning capacity requirements for patients with suspected cardiac transthyretin amyloidosis
  55. Editorial: Edema in heart failure with reduced ejection fraction
  56. Genetic architecture of the HLA/MHC locus in cardiometabolic disease, severe mental illness, and related traits.
  57. The incremental value of multi-organ assessment of congestion using ultrasound in outpatients with heart failure
  58. Identification and quantification of congestion in heart failure: a work in progress
  59. Correction: Diuretic dose trajectories in dilated cardiomyopathy: prognostic implications
  60. Which frailty tool best predicts morbidity and mortality in ambulatory patients with heart failure? A prospective study
  61. Diuretic dose trajectories in dilated cardiomyopathy: prognostic implications
  62. Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials
  63. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial
  64. Ketone Bodies in Acute Heart Failure: Fuel for Thought
  65. Early and late renal function changes with spironolactone in patients at risk of developing heart failure: findings from the HOMAGE trial
  66. Implanted haemodynamic telemonitoring devices to guide management of heart failure: a review and meta-analysis of randomised trials
  67. Chronic kidney disease (CKD) and CKD ‐ism in heart failure – what a mess!
  68. Optimal Management of Heart Failure and Chronic Obstructive Pulmonary Disease: Clinical Challenges
  69. Reply to ‘Particular challenges in the use of pulmonary vasodilating therapy for patients with pulmonary hypertension secondary to left heart disease’
  70. Albuminuria as a marker of systemic congestion in patients with heart failure
  71. Dyskalemia in people at increased risk for heart failure: findings from the heart ‘OMics’ in AGEing (HOMAGE) trial
  72. Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions
  73. Rationale and design of a randomised trial of intravenous iron in patients with heart failure
  74. Clinical implications of left atrial changes after optimization of medical therapy in patients with heart failure
  75. The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trial
  76. Dynamic risk stratification using Markov chain modelling in patients with chronic heart failure
  77. Are non-invasive estimations of plasma volume an accurate measure of congestion in patients with chronic heart failure?
  78. Remote laser-speckle sensing of heart sounds for health assessment and biometric identification
  79. Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo‐controlled multicentre trial
  80. Heart failure: age is no excuse for complacency
  81. Chronic Obstructive Pulmonary Disease and Heart Failure
  82. Predicting mortality after hospitalisation for COPD using electronic health records
  83. Practical outpatient management of worsening chronic heart failure
  84. Comparing and contrasting risk factors for heart failure in patients with and without history of myocardial infarction: data from HOMAGE and the UK Biobank
  85. Therapeutic inertia in the pharmacological management of heart failure with reduced ejection fraction
  86. Only people with increased plasma concentrations of natriuretic peptides should be included in outcome trials of diabetes, cardiovascular and kidney disease: implications for clinical practice
  87. Influence of ejection fraction on biomarker expression and response to spironolactone in people at risk of heart failure: findings from the HOMAGE trial
  88. Criteria for Iron Deficiency in Patients With Heart Failure
  89. Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: A systematic review and meta-analysis of randomised trials
  90. Assessment of Phasic Changes of Vascular Size by Automated Edge Tracking-State of the Art and Clinical Perspectives
  91. Prognostic Value and Therapeutic Utility of Lung Ultrasound in Acute and Chronic Heart Failure
  92. Hypochloraemia following admission to hospital with heart failure is common and associated with an increased risk of readmission or death: a report from OPERA-HF
  93. Biomarker‐based assessment of collagen cross‐linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial
  94. The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial
  95. No influence of spironolactone on plasma concentrations of angiotensin-converting enzyme 2: Findings from the HOMAGE randomized trial
  96. The effect of digoxin on renal function in patients with heart failure
  97. The prevalence and clinical associations of ultrasound measures of congestion in patients at risk of developing heart failure
  98. Congestion in Patients with Advanced Heart Failure
  99. To master heart failure, first master congestion
  100. Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: Implications for future trial design
  101. Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial
  102. A novel treatment for heart failure targets myocardial fibrosis
  103. Ethnic differences in prevalence of actionable HbA1c levels in UK Biobank: implications for screening
  104. Use of Social Media by Cardiovascular Health Care Professionals
  105. Reply to the letter regarding the article ‘Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure’
  106. Remote history of VTE is associated with severe COVID‐19 in middle and older age: UK Biobank cohort study
  107. A comparison of non‐invasive methods of measuring body composition in patients with heart failure: a report from SICA‐HF
  108. Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure
  109. Use of diuretics and outcomes in patients with type 2 diabetes: Findings from the EMPA‐REG OUTCOME trial
  110. Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial
  111. The struggle towards a Universal Definition of Heart Failure—how to proceed?
  112. Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF
  113. Intravenous iron for heart failure with evidence of iron deficiency: a meta-analysis of randomised trials
  114. Prognostic value of the chest X-ray in patients hospitalised for heart failure
  115. The value of spot urinary creatinine as a marker of muscle wasting in patients with new‐onset or worsening heart failure
  116. COVID-19 and its cardiovascular effects: a systematic review of prevalence studies
  117. The Effect of Digoxin on Renal Function in Patients with Heart Failure
  118. The association between blood groups and COVID‐19 infection: a study from the UK Biobank
  119. Effect of frailty on treatment, hospitalisation and death in patients with chronic heart failure
  120. The impact of malnutrition on short-term morbidity and mortality in ambulatory patients with heart failure
  121. Ultrasound imaging of congestion in heart failure: examinations beyond the heart
  122. Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME
  123. Association between right-sided cardiac function and ultrasound-based pulmonary congestion on acutely decompensated heart failure: findings from a pooled analysis of four cohort studies
  124. Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data
  125. Structural heart disease, cardiac dysfunction and heart failure: the ambiguity of a definition
  126. Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial
  127. Driving Habits and Reaction Times on a Driving Simulation in Older Drivers With Chronic Heart Failure
  128. Caring for people with heart failure and many other medical problems through and beyond the COVID ‐19 pandemic: the advantages of universal access to home telemonitoring
  129. At the heart of COVID-19
  130. Association Between Walking Pace and Stroke Incidence
  131. Ultrasound indices of congestion in patients with acute heart failure according to body mass index
  132. Agreement and Classification Performance of Malnutrition Tools in Patients with Chronic Heart Failure
  133. Eplerenone prevents an increase in serum carboxy‐terminal propeptide of procollagen type I after myocardial infarction complicated by left ventricular dysfunction and/or heart failure
  134. Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof‐of‐concept, randomised, precision‐medicine, prevention trial. The Heart OMics in AGing ...
  135. OUP accepted manuscript
  136. Chronic Obstructive Pulmonary Disease and Heart Failure
  137. Association of Fitness and Grip Strength With Heart Failure
  138. Myocardial Dysfunction and Coronary Artery Disease as Therapeutic Targets in Heart Failure
  139. Prevalence and Incidence of Atrial Fibrillation in Ambulatory Patients with Heart Failure
  140. High sensitivity C-Reactive Protein in Chronic Heart Failure: Patient Characteristics, Phenotypes and Mode of Death
  141. New perspectives and future directions in the treatment of heart failure
  142. Prevention or Procrastination for Heart Failure?
  143. Clinical and prognostic association of total atrial conduction time in patients with heart failure
  144. Identification of Frailty in Chronic Heart Failure
  145. Prevalence, pattern and clinical relevance of ultrasound indices of congestion in outpatients with heart failure
  146. The prognostic role of different renal function phenotypes in patients with acute heart failure
  147. Dynamic risk stratification using serial measurements of plasma concentrations of natriuretic peptides in patients with heart failure
  148. Walking Pace Is Associated with Lower Risk of All-Cause and Cause-Specific Mortality
  149. Warm water immersion in patients with chronic heart failure: a pilot study
  150. Malnutrition, congestion and mortality in ambulatory patients with heart failure
  151. Effect of beta-adrenergic blockade on weight changes in patients with chronic heart failure
  152. Iron deficiency in patients with heart failure with preserved ejection fraction and its association with reduced exercise capacity, muscle strength and quality of life
  153. Losing Track by Tracking Speckles
  154. Body mass index and all-cause mortality in heart failure patients with normal and reduced ventricular ejection fraction: a dose–response meta-analysis
  155. Low serum chloride in patients with chronic heart failure: clinical associations and prognostic significance
  156. Prevalence and Prognostic Significance of Malnutrition Using 3 Scoring Systems Among Outpatients With Heart Failure
  157. Effect of increased inspired oxygen on exercise performance in patients with heart failure and normal ejection fraction
  158. Prognostic value of psychosocial factors for first and recurrent hospitalizations and mortality in heart failure patients: insights from the OPERA-HF study
  159. Clinical and prognostic relationships of pulmonary artery to aorta diameter ratio in patients with heart failure: a cardiac magnetic resonance imaging study
  160. Prevalence, predictors, and prognostic implications of PR interval prolongation in patients with heart failure
  161. Time to Take the Failure Out of Heart Failure
  162. Interatrial shunt devices for heart failure with normal ejection fraction: a technology update
  163. Pharmacological and Non-pharmacological Treatment for Decompensated Heart Failure: What Is New?
  164. This patient is not breathing properly: is this COPD, heart failure, or neither?
  165. Takotsubo syndrome in the paediatric population
  166. Non-invasive measurement of right atrial pressure by near-infrared spectroscopy: preliminary experience. A report from the SICA-HF study
  167. The effects of short-term omission of daily medication on the pathophysiology of heart failure
  168. New pharmacological approaches in heart failure therapy: developments and possibilities
  169. What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan?
  170. Prognostic value of simple frailty and malnutrition screening tools in patients with acute heart failure due to left ventricular systolic dysfunction
  171. Terapia diuretica nell’insufficienza cardiaca cronica: evidenze, esperienze, prospettive
  172. Is Swimming Safe in Heart Failure? A Systematic Review
  173. Renal function estimation and Cockcroft–Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart ‘OMics’ in AGEing (HOMAGE) and the high-risk myocar...
  174. Cardiac Dysfunction, Congestion and Loop Diuretics: their Relationship to Prognosis in Heart Failure
  175. Sarcopenia in patients with heart failure with preserved ejection fraction: Impact on muscle strength, exercise capacity and quality of life
  176. Tachycardia-induced cardiomyopathy in pregnancy
  177. PARADIGM-HF: does dose matter?
  178. Prevalence and Outcomes of Anemia and Hematinic Deficiencies in Patients With Chronic Heart Failure
  179. Taxonomy of segmental myocardial systolic dysfunction
  180. Regional circulatory distribution of novel cardiac bio-markers and their relationships with haemodynamic measurements
  181. New ways to visualize and combat congestion in heart failure
  182. Is the diagnostic coding position of acute heart failure related to mortality? A report from the Euro Heart Failure Survey-1
  183. The effect of increasing inspired oxygen on exercise performance in patients with chronic heart failure
  184. Exploring quality of life in patients with and without heart failure
  185. Betabloccanti in pazienti con scompenso cardiaco e fibrillazione atriale
  186. Clinical trials update from the European Society of Cardiology-Heart Failure meeting 2015: AUGMENT-HF, TITRATION, STOP-HF, HARMONIZE, LION HEART, MOOD-HF, and renin-angiotensin inhibitors in patients with heart and renal failure
  187. The Prevalence of Iron Deficiency in Patients with Heart Failure with Preserved Ejection Fraction and its Association with Elevated Pulmonary Pressure, Reduced Exercise Capacity and Quality of Life
  188. Prognostic significance of ultrasound-assessed jugular vein distensibility in heart failure
  189. The Obesity Paradox in Type 2 Diabetes Mellitus: Relationship of Body Mass Index to Prognosis
  190. The relationship of QRS morphology with cardiac structure and function in patients with heart failure
  191. If home telemonitoring reduces mortality in heart failure, is this just due to better guideline-based treatment?
  192. Update on management of heart failure with preserved ejection fraction
  193. Prescribing Patterns to Optimize Heart Rate
  194. Is the Epidemic of Heart Disease Really Over or Just Evolving?
  195. Patent Ductus Arteriosus in Older Adults: Incidental Finding or Relevant Pathology?
  196. The Prevalence of Extra-cranial Carotid Artery Disease in Chronic Heart Failure
  197. Fluid Management In Patients With Chronic Heart Failure
  198. Heart failure with preserved ejection fraction
  199. Clinical trials update from the European Society of Cardiology meeting 2014: PARADIGM‐HF, CONFIRM‐HF, SIGNIFY, atrial fibrillation, beta‐blockers and heart failure, and vagal stimulation in heart failure
  200. Left atrial function measured by cardiac magnetic resonance imaging in patients with heart failure: clinical associations and prognostic value
  201. Lipid-Modifying Treatments for Heart Failure
  202. Does Speckle Tracking Really Improve Diagnosis and Risk Stratification in Patients With HF With Normal EF?
  203. Diagnostic Accuracy of Left Ventricular Systolic Dysfunction in Routine Clinical Practice-Classifying the Unclassified
  204. Muscle Wasting in Patients with Heart Failure with Preserved Ejection Fraction and Its Impact on Muscle Strength and Functional Capacity during Exercise
  205. Remote telemonitoring for patients with heart failure: might monitoring pulmonary artery pressure become routine?
  206. Clinical Trials in Patients with Heart Failure and Preserved Left Ventricular Ejection Fraction
  207. Telemonitoring in heart failure: Big Brother watching over you
  208. THE OBESITY PARADOX IN TYPE II DIABETES MELLITUS: IMPACT OF BODY MASS INDEX ON PROGNOSIS
  209. Multiple Cardiac Clots in an Individual with Essential Thrombocythemia and Heart Failure
  210. The in vitro stability of novel cardiovascular and sepsis biomarkers at ambient temperature
  211. Revisiting a classical clinical sign: Jugular venous ultrasound
  212. Global longitudinal strain in patients with suspected heart failure and a normal ejection fraction: does it improve diagnosis and risk stratification?
  213. Case Selection for Cardiac Resynchronization in Atrial Fibrillation
  214. Old and newer biomarkers in heart failure
  215. Does cirrhotic cardiomyopathy exist? 50 years of uncertainty
  216. Intravenous versus intracoronary bolus of glycoprotein IIb/IIIa inhibitor administration during primary percutaneous coronary intervention on long-term left ventricular systolic and diastolic function
  217. Why Does CRT Reduce the Risk of Arrhythmias?
  218. Fish Oil vs Olive Oil for Postoperative Atrial Fibrillation
  219. Cardiac dysfunction in cirrhosis is not associated with the severity of liver disease
  220. Defining Diastolic Heart Failure and Identifying Effective Therapies
  221. Medical Management of Stable Coronary Atherosclerosis
  222. IVC Diameter in Patients With Chronic Heart Failure
  223. An atrial mass
  224. A Meta-Analysis of the Therapeutic Effects of Glucagon-Like Peptide-1 Agonist in Heart Failure
  225. Renal dysfunction in acute and chronic heart failure: prevalence, incidence and prognosis
  226. Subclinical Anthracycline Cardiotoxicity in Patients With Acute Promyelocytic Leukemia in Long‐Term Remission After the AIDA Protocol
  227. Clinical Trials Update from the American Heart Association Meeting 2010: EMPHASIS-HF, RAFT, TIM-HF, Tele-HF, ASCEND-HF, ROCKET-AF, and PROTECT
  228. Cor triatriatum: Transoesophageal three-dimensional reconstruction shows exact membrane morphology